Anita Kumar, MD | Authors

RITE AID PENNSYLVANIA INC

135 SUNSET AVE

Articles

The Emerging Role of Checkpoint Inhibitor Therapy in Hodgkin Lymphoma

October 15, 2016

Ultimately, the management goal is not for patients with relapsed/refractory disease to live with chronic Hodgkin lymphoma while receiving immune checkpoint blockade therapy, but rather to cure more patients with first- or second-line therapy.